MAP2K7 and pancreatic ductal adenocarcinoma: Targeted therapies are diversifying treatment options in pancreatic ductal adenocarcinoma; however, numerous studies have also attempted to target other related signaling molecules, such as EGFR, MEK, and PI3K (Qian et al. 2020).